IO Biotech (IOBT) News Today $0.90 -0.04 (-4.26%) Closing price 01/31/2025 03:54 PM EasternExtended Trading$0.90 0.00 (0.00%) As of 01/31/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period IO Biotech, Inc. (NASDAQ:IOBT) Short Interest UpdateIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 45,400 shares, a decline of 68.6% from the December 31st total of 144,400 shares. Approximately 0.1% of the company's stock are sold short. Based on an average daily volume of 358,100 shares, the short-interest ratio is currently 0.1 days.January 28, 2025 | marketbeat.comJefferies maintains IO Biotech Buy rating, $8 target on PFS hopesJanuary 28, 2025 | msn.comIO Biotech, Inc. (NASDAQ:IOBT) Sees Large Decrease in Short InterestIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 45,400 shares, a decrease of 68.6% from the December 15th total of 144,400 shares. Based on an average daily trading volume, of 358,100 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the company are sold short.January 14, 2025 | marketbeat.comIO Biotech completes enrollment in Phase 2 trial of IO102-IO103January 10, 2025 | markets.businessinsider.comIO Biotech Completes Phase 2 Enrollment Ahead Of Schedule For IO102-IO103 Cancer Vaccine TrialJanuary 10, 2025 | markets.businessinsider.comIO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck CancerJanuary 9, 2025 | globenewswire.comIO Biotech, Inc. (NASDAQ:IOBT) Short Interest Up 210.5% in DecemberIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 144,400 shares, an increase of 210.5% from the November 30th total of 46,500 shares. Based on an average daily volume of 349,900 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.3% of the shares of the company are sold short.December 26, 2024 | marketbeat.comIO Biotech, Inc. (NASDAQ:IOBT) CEO Acquires $10,125.00 in StockIO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) CEO Mai-Britt Zocca bought 12,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.81 per share, for a total transaction of $10,125.00. Following the completion of the acquisition, the chief executive officer now owns 49,891 shares in the company, valued at approximately $40,411.71. This trade represents a 33.43 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.December 23, 2024 | marketbeat.comIO Biotech secures up to €57.5 million in debt financing from the European Investment BankDecember 20, 2024 | globenewswire.comIO Biotech (NASDAQ:IOBT) Shares Down 1.3% - Here's What HappenedIO Biotech (NASDAQ:IOBT) Stock Price Down 1.3% - Should You Sell?December 20, 2024 | marketbeat.comIO Biotech amends bylaws and adjusts fiscal year-endDecember 19, 2024 | uk.investing.comHC Wainwright Cuts Earnings Estimates for IO BiotechIO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for shares of IO Biotech in a research note issued on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earningsNovember 15, 2024 | marketbeat.comPromising Prospects for IO Biotech Driven by Phase 3 Melanoma Study and Strong Financial PositionNovember 14, 2024 | markets.businessinsider.comPositive Outlook for IO Biotech Amid Promising Clinical Developments in Melanoma and Head & Neck Cancer TrialsNovember 13, 2024 | markets.businessinsider.comPromising Clinical Progress and Financial Stability Drive Buy Rating for IO BiotechNovember 13, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for IO Biotech (NASDAQ:IOBT)HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of IO Biotech in a report on Tuesday.November 12, 2024 | marketbeat.comIO Biotech Reports Third Quarter 2024 Financial Results and Provides Business HighlightsNovember 12, 2024 | globenewswire.comIO Biotech Announces Participation in Upcoming Investor ConferencesNovember 11, 2024 | globenewswire.comPromising Potential of IO Biotech: Buy Rating Backed by Strong Phase 2 Data and Strategic Growth PlansNovember 8, 2024 | markets.businessinsider.comIO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 StudyNovember 7, 2024 | globenewswire.comIO Biotech Receives Buy Rating Amid Promising Phase 2 Results and Future Potential in Cancer TreatmentsNovember 7, 2024 | markets.businessinsider.comHere's Why We're A Bit Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn SituationNovember 3, 2024 | finance.yahoo.comShort Interest in IO Biotech, Inc. (NASDAQ:IOBT) Declines By 12.7%IO Biotech, Inc. (NASDAQ:IOBT - Get Free Report) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 277,100 shares, a drop of 12.7% from the September 30th total of 317,500 shares. Currently, 0.6% of the company's shares are sold short. Based on an average trading volume of 410,000 shares, the days-to-cover ratio is currently 0.7 days.October 29, 2024 | marketbeat.comNovo Holdings A S Has $3.52 Million Position in IO Biotech, Inc. (NASDAQ:IOBT)Novo Holdings A S trimmed its position in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) by 24.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,354,449 shares of the company's stock after seOctober 27, 2024 | marketbeat.comBuy Rating on IO Biotech’s IO102/103 Fueled by Positive KOL Feedback and Phase 2 DataOctober 4, 2024 | markets.businessinsider.comIO Biotech (NASDAQ:IOBT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 4, 2024 | markets.businessinsider.comIO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 4, 2024 | globenewswire.comNovo Holdings A S Sells 658,809 Shares of IO Biotech, Inc. (NASDAQ:IOBT)Novo Holdings A S lessened its position in shares of IO Biotech, Inc. (NASDAQ:IOBT - Free Report) by 12.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,429,449 shares of the company's stock after selling 658,809 shareSeptember 30, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for IO Biotech (IOBT)September 16, 2024 | markets.businessinsider.comBuy Rating for IO Biotech Backed by Promising ESMO Data and Superior Efficacy of IO102-IO103 Combination TherapySeptember 16, 2024 | markets.businessinsider.comIO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck CancerSeptember 14, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)September 5, 2024 | markets.businessinsider.comOptimistic Outlook on IO Biotech’s PFS Improvements Despite ORR SetbackSeptember 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for IO Biotech Amid Positive Phase 3 Trial Progress and Historical DataSeptember 3, 2024 | markets.businessinsider.comIO Biotech (NASDAQ:IOBT) Receives "Overweight" Rating from Piper SandlerPiper Sandler reiterated an "overweight" rating and set a $10.00 target price on shares of IO Biotech in a research note on Tuesday.September 3, 2024 | marketbeat.comIO Biotech (NASDAQ:IOBT) Given New $4.00 Price Target at Morgan StanleyMorgan Stanley reduced their target price on IO Biotech from $7.00 to $4.00 and set an "overweight" rating for the company in a research report on Tuesday.September 3, 2024 | marketbeat.comIO Biotech's Phase 3 Trial Data Fails To Show Superiority In ORR For IO102-IO103 With KEYTRUDAAugust 31, 2024 | markets.businessinsider.comIO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced MelanomaAugust 30, 2024 | globenewswire.comIO Biotech Announces Participation in Upcoming Investor ConferencesAugust 26, 2024 | globenewswire.comQ3 2024 EPS Estimates for IO Biotech, Inc. Decreased by HC Wainwright (NASDAQ:IOBT)IO Biotech, Inc. (NASDAQ:IOBT - Free Report) - Stock analysts at HC Wainwright reduced their Q3 2024 earnings estimates for IO Biotech in a research note issued on Wednesday, August 14th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings per share of ($0.35) for theAugust 16, 2024 | marketbeat.comBuy Rating Affirmed on IO Biotech Amid Positive Phase 3 Study Prospects and Strong Financial FootingAugust 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: IO Biotech (IOBT), Gritstone Oncology (GRTS) and Korro Bio (KRRO)August 15, 2024 | markets.businessinsider.comIO Biotech (NASDAQ:IOBT) Posts Earnings Results, Beats Estimates By $0.04 EPSIO Biotech (NASDAQ:IOBT - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.04.August 14, 2024 | marketbeat.comIO Biotech (NASDAQ:IOBT) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $12.00 price objective on shares of IO Biotech in a research note on Wednesday.August 14, 2024 | marketbeat.comThis 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics StockAugust 14, 2024 | msn.comIO Biotech Reports Second Quarter 2024 Financial Results and Provides Business HighlightsAugust 13, 2024 | globenewswire.com3 Penny Stocks with 190% Growth Potential According to Wall Street AnalystsAugust 12, 2024 | 247wallst.comIovance Biotherapeutics Shares Rise 27% After 2Q Revenue BeatAugust 9, 2024 | marketwatch.comHoldings A/S Novo Sells 51,522 Shares of IO Biotech, Inc. (NASDAQ:IOBT) StockJuly 28, 2024 | insidertrades.com Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address IOBT Media Mentions By Week IOBT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOBT News Sentiment▼1.210.69▲Average Medical News Sentiment IOBT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOBT Articles This Week▼41▲IOBT Articles Average Week Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies C4 Therapeutics News Today Benitec Biopharma News Today COMPASS Pathways News Today Amylyx Pharmaceuticals News Today Canopy Growth News Today UroGen Pharma News Today Atai Life Sciences News Today Amarin News Today Foghorn Therapeutics News Today Neurogene News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IOBT) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
